☰

Andrea Giuffrida - Publications

Affiliations: 
University of Texas Health Science Center, San Antonio, TX, United States 
Area:
Cannabinoids, Neuroscience, Pharmacology
Tree Info Grants Similar researchers PubMed Report error

59 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Seillier A, Martinez AA, Giuffrida A. Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model. Plos One. 15: e0230238. PMID 32163506 DOI: 10.1371/Journal.Pone.0230238  0.371
2018 Perez SM, Donegan JJ, Boley AM, Aguilar DD, Giuffrida A, Lodge DJ. Ventral hippocampal overexpression of Cannabinoid Receptor Interacting Protein 1 (CNRIP1) produces a schizophrenia-like phenotype in the rat. Schizophrenia Research. PMID 30522798 DOI: 10.1016/J.Schres.2018.11.006  0.363
2017 Seillier A, Giuffrida A. The cannabinoid transporter inhibitor OMDM-2 reduces social interaction: Further evidence for transporter-mediated endocannabinoid release. Neuropharmacology. 130: 1-9. PMID 29169961 DOI: 10.1016/J.Neuropharm.2017.11.032  0.321
2017 Seillier A, Giuffrida A. Anxiety does not contribute to social withdrawal in the subchronic phencyclidine rat model of schizophrenia. Behavioural Pharmacology. PMID 28704273 DOI: 10.1097/Fbp.0000000000000325  0.304
2016 Matricon J, Seillier A, Giuffrida A. Distinct neuronal activation patterns are associated with PCP-induced social withdrawal and its reversal by the endocannabinoid-enhancing drug URB597. Neuroscience Research. PMID 27091613 DOI: 10.1016/J.Neures.2016.04.004  0.317
2015 Seillier A, Giuffrida A. Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 26706691 DOI: 10.1016/J.Euroneuro.2015.12.009  0.321
2015 Aguilar DD, Giuffrida A, Lodge DJ. THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia. Journal of Psychopharmacology (Oxford, England). PMID 26510449 DOI: 10.1177/0269881115612239  0.352
2015 Perez SM, Aguilar DD, Neary JL, Carless MA, Giuffrida A, Lodge DJ. Schizophrenia-Like Phenotype Inherited by the F2 Generation of a Gestational Disruption Model of Schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 26068729 DOI: 10.1038/Npp.2015.169  0.332
2015 Bilbao A, Serrano A, Cippitelli A, Pavón FJ, Giuffrida A, Suárez J, García-Marchena N, Baixeras E, Gómez de Heras R, Orio L, Alén F, Ciccocioppo R, Cravatt BF, Parsons LH, Piomelli D, et al. Role of the satiety factor oleoylethanolamide in alcoholism. Addiction Biology. PMID 26037332 DOI: 10.1111/Adb.12276  0.438
2015 Martinez AA, Morgese MG, Pisanu A, Macheda T, Paquette MA, Seillier A, Cassano T, Carta AR, Giuffrida A. Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Neurobiology of Disease. 74: 295-304. PMID 25486547 DOI: 10.1016/J.Nbd.2014.11.024  0.371
2014 Seillier A, Dominguez Aguilar D, Giuffrida A. The dual FAAH/MAGL inhibitor JZL195 has enhanced effects on endocannabinoid transmission and motor behavior in rats as compared to those of the MAGL inhibitor JZL184. Pharmacology, Biochemistry, and Behavior. 124: 153-9. PMID 24911644 DOI: 10.1016/J.Pbb.2014.05.022  0.33
2014 Giuffrida A, Matricon J, Seillier A. ENDOCANNABINOID-ENHANCING DRUGS REVERSE SOCIAL WITHDRAWAL IN THE PCP RAT MODEL OF SCHIZOPHRENIA Schizophrenia Research. 153: S46. DOI: 10.1016/S0920-9964(14)70151-3  0.304
2013 Seillier A, Martinez AA, Giuffrida A. Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 1816-24. PMID 23563893 DOI: 10.1038/Npp.2013.81  0.347
2012 Denora N, Cassano T, Laquintana V, Lopalco A, Trapani A, Cimmino CS, Laconca L, Giuffrida A, Trapani G. Novel codrugs with GABAergic activity for dopamine delivery in the brain. International Journal of Pharmaceutics. 437: 221-31. PMID 22940209 DOI: 10.1016/J.Ijpharm.2012.08.023  0.318
2012 Giuffrida A, Seillier A. New insights on endocannabinoid transmission in psychomotor disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 38: 51-8. PMID 22521335 DOI: 10.1016/J.Pnpbp.2012.04.002  0.373
2012 Martinez A, Macheda T, Morgese MG, Trabace L, Giuffrida A. The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. Neuroscience Research. 72: 236-42. PMID 22192465 DOI: 10.1016/J.Neures.2011.12.006  0.319
2011 Seillier A, Giuffrida A. Inhibition of fatty acid amide hydrolase modulates anxiety-like behavior in PCP-treated rats. Pharmacology, Biochemistry, and Behavior. 98: 583-6. PMID 21421000 DOI: 10.1016/J.Pbb.2011.03.010  0.307
2010 Solbrig MV, Fan Y, Hermanowicz N, Morgese MG, Giuffrida A. A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats. Experimental Neurology. 226: 231-41. PMID 20832403 DOI: 10.1016/J.Expneurol.2010.09.003  0.323
2010 Seillier A, Advani T, Cassano T, Hensler JG, Giuffrida A. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 13: 373-86. PMID 19607756 DOI: 10.1017/S146114570999023X  0.377
2010 Giuffrida A, McMahon LR. In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins & Other Lipid Mediators. 91: 90-103. PMID 19523530 DOI: 10.1016/J.Prostaglandins.2009.05.004  0.327
2009 Seillier A, Giuffrida A. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behavioural Brain Research. 204: 410-5. PMID 19716985 DOI: 10.1016/J.Bbr.2009.02.007  0.353
2009 Fride E, Gobshtis N, Dahan H, Weller A, Giuffrida A, Ben-Shabat S. The endocannabinoid system during development: emphasis on perinatal events and delayed effects. Vitamins and Hormones. 81: 139-58. PMID 19647111 DOI: 10.1016/S0083-6729(09)81006-6  0.301
2009 Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, Strong R, Lutz B, Marsicano G, Roberts JL, Giuffrida A. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. The European Journal of Neuroscience. 29: 2177-86. PMID 19490092 DOI: 10.1111/J.1460-9568.2009.06764.X  0.354
2009 Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, Klosterkötter J, Piomelli D, Leweke FM. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. The British Journal of Psychiatry : the Journal of Mental Science. 194: 371-2. PMID 19336792 DOI: 10.1192/Bjp.Bp.108.053843  0.497
2009 Koethe D, Schreiber D, Giuffrida A, Mauss C, Faulhaber J, Heydenreich B, Hellmich M, Graf R, Klosterkötter J, Piomelli D, Leweke FM. Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid. Journal of Neural Transmission (Vienna, Austria : 1996). 116: 301-5. PMID 19137236 DOI: 10.1007/S00702-008-0169-6  0.444
2009 Morgese MG, Cassano T, Gaetani S, Macheda T, Laconca L, Dipasquale P, Ferraro L, Antonelli T, Cuomo V, Giuffrida A. Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochemistry International. 54: 56-64. PMID 19010365 DOI: 10.1016/J.Neuint.2008.10.007  0.332
2008 Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, Klosterkoetter J, Piomelli D, Leweke F. P.3.f.001 Does anandamide elevation in cerebrospinal fluid protect against transition into frank psychosis? European Neuropsychopharmacology. 18: S474. DOI: 10.1016/S0924-977X(08)70706-5  0.417
2007 Morgese MG, Cassano T, Cuomo V, Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Experimental Neurology. 208: 110-9. PMID 17900568 DOI: 10.1016/J.Expneurol.2007.07.021  0.368
2007 Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M, Klosterkötter J, Piomelli D. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophrenia Research. 94: 29-36. PMID 17566707 DOI: 10.1016/J.Schres.2007.04.025  0.465
2007 Ferrer B, Bermúdez-Silva FJ, Bilbao A, Alvarez-Jaimes L, Sanchez-Vera I, Giuffrida A, Serrano A, Baixeras E, Khaturia S, Navarro M, Parsons LH, Piomelli D, Rodríguez de Fonseca F. Regulation of brain anandamide by acute administration of ethanol. The Biochemical Journal. 404: 97-104. PMID 17302558 DOI: 10.1042/Bj20061898  0.462
2007 Price DA, Owens WA, Gould GG, Frazer A, Roberts JL, Daws LC, Giuffrida A. CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. Journal of Neurochemistry. 101: 389-96. PMID 17250681 DOI: 10.1111/J.1471-4159.2006.04383.X  0.331
2007 Schreiber D, Harlfinger S, Nolden BM, Gerth CW, Jaehde U, Schömig E, Klosterkötter J, Giuffrida A, Astarita G, Piomelli D, Markus Leweke F. Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Analytical Biochemistry. 361: 162-8. PMID 17196922 DOI: 10.1016/J.Ab.2006.11.027  0.459
2005 Solbrig MV, Adrian R, Baratta J, Piomelli D, Giuffrida A. A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena. Experimental Neurology. 194: 355-62. PMID 16022863 DOI: 10.1016/J.Expneurol.2005.02.017  0.471
2005 Leweke F, Giuffrida A, Koethe D, Nolden B, Gerth C, Schreiber D, Gross S, Juelicher A, Klosterkötter J, Piomelli D. The role of the endogenous cannabinoid system in schizophrenia Pharmacopsychiatry. 38. DOI: 10.1055/s-2005-918765  0.395
2004 Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkötter J, Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 29: 2108-14. PMID 15354183 DOI: 10.1038/Sj.Npp.1300558  0.519
2004 Leweke F, Giuffrida A, Koethe D, Schreiber D, Gerth C, Piomelli D, Klosterkötter J. P.2.143 Does cannabis use affect endogenouscannabinoids in schizophrenia? European Neuropsychopharmacology. 14: S295. DOI: 10.1016/S0924-977X(04)80363-8  0.44
2003 Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A. Exercise activates the endocannabinoid system. Neuroreport. 14: 2209-11. PMID 14625449 DOI: 10.1097/00001756-200312020-00015  0.413
2003 Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. The European Journal of Neuroscience. 18: 1607-14. PMID 14511339 DOI: 10.1046/J.1460-9568.2003.02896.X  0.53
2003 Leweke F, Giuffrida A, Gerth C, Klosterko¨tter J, Piomelli D. Evidence for a role of endogenous cannabinoids in schizophrenia Schizophrenia Research. 60: 101. DOI: 10.1016/S0920-9964(03)80828-9  0.466
2002 Schuel H, Burkman LJ, Lippes J, Crickard K, Forester E, Piomelli D, Giuffrida A. N-Acylethanolamines in human reproductive fluids. Chemistry and Physics of Lipids. 121: 211-27. PMID 12505702 DOI: 10.1016/S0009-3084(02)00158-5  0.501
2002 Schuel H, Burkman LJ, Lippes J, Crickard K, Mahony MC, Giuffrida A, Picone RP, Makriyannis A. Evidence that anandamide-signaling regulates human sperm functions required for fertilization. Molecular Reproduction and Development. 63: 376-87. PMID 12237954 DOI: 10.1002/Mrd.90021  0.303
2002 Schäbitz WR, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S, Piomelli D. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke; a Journal of Cerebral Circulation. 33: 2112-4. PMID 12154273 DOI: 10.1161/01.Str.0000023491.63693.18  0.446
2002 Leweke F, Giuffrida A, Gerth C, Faulhaber J, Klosterkötter K, Piomelli D. Endocannabinoids in schizophrenia and other psychiatric disorders European Psychiatry. 17: 156. DOI: 10.1016/S0924-9338(02)80679-4  0.444
2001 Rodríguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Nava F, Fu J, Murillo-Rodríguez E, Giuffrida A, LoVerme J, Gaetani S, Kathuria S, Gall C, Piomelli D. An anorexic lipid mediator regulated by feeding. Nature. 414: 209-12. PMID 11700558 DOI: 10.1038/35102582  0.712
2001 Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. The Journal of Pharmacology and Experimental Therapeutics. 298: 7-14. PMID 11408519  0.46
2001 Burkman L, Schuel H, Lippes J, Makriyannis A, Giuffrida A, Piomelli D. Endocannabinoids: Discovery of a unique signaling system for regulating sperm function and fertilization. Fertility and Sterility. 76: S202-S203. DOI: 10.1016/S0015-0282(01)02602-4  0.368
2000 Giuffrida A, Piomelli D. The endocannabinoid system: a physiological perspective on its role in psychomotor control. Chemistry and Physics of Lipids. 108: 151-8. PMID 11106788 DOI: 10.1016/S0009-3084(00)00193-6  0.505
2000 Calignano A, Kátona I, Désarnaud F, Giuffrida A, La Rana G, Mackie K, Freund TF, Piomelli D. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature. 408: 96-101. PMID 11081515 DOI: 10.1038/35040576  0.481
2000 Giuffrida A, Rodriguez de Fonseca F, Nava F, Loubet-Lescoulié P, Piomelli D. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. European Journal of Pharmacology. 408: 161-8. PMID 11080522 DOI: 10.1016/S0014-2999(00)00786-X  0.5
2000 Piomelli D, Giuffrida A, Calignano A, Rodríguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends in Pharmacological Sciences. 21: 218-24. PMID 10838609 DOI: 10.1016/S0165-6147(00)01482-6  0.504
2000 Giuffrida A, Rodríguez de Fonseca F, Piomelli D. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Analytical Biochemistry. 280: 87-93. PMID 10805525 DOI: 10.1006/Abio.2000.4509  0.456
2000 Giuffrida A, Désarnaud F, Piomelli D. Endogenous cannabinoid signaling and psychomotor disorders. Prostaglandins & Other Lipid Mediators. 61: 63-70. PMID 10785542 DOI: 10.1016/S0090-6980(00)00055-1  0.495
2000 Beltramo M, de Fonseca FR, Navarro M, Calignano A, Gorriti MA, Grammatikopoulos G, Sadile AG, Giuffrida A, Piomelli D. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 3401-7. PMID 10777802 DOI: 10.1523/Jneurosci.20-09-03401.2000  0.538
2000 Piomelli D, Giuffrida A. Reply: cannabinoid paths to anti-diarrheal drugs Trends in Pharmacological Sciences. 21: 373. DOI: 10.1016/S0165-6147(00)01539-X  0.471
1999 Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 10: 1665-9. PMID 10501554 DOI: 10.1097/00001756-199906030-00008  0.512
1999 Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neuroscience. 2: 358-63. PMID 10204543 DOI: 10.1016/S0090-6980(99)90286-1  0.516
1998 Piomelli D, Beltramo M, Giuffrida A, Stella N. Endogenous cannabinoid signaling. Neurobiology of Disease. 5: 462-73. PMID 9974178 DOI: 10.1006/Nbdi.1998.0221  0.58
1998 Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394: 277-81. PMID 9685157 DOI: 10.1038/28393  0.481
1998 Giuffrida A, Piomelli D. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. Febs Letters. 422: 373-6. PMID 9498819 DOI: 10.1016/S0014-5793(98)00046-5  0.463
Show low-probability matches.